Therapeutic uses of complement receptor 2
    1.
    发明授权
    Therapeutic uses of complement receptor 2 失效
    补体受体2的治疗用途

    公开(公告)号:US07378094B2

    公开(公告)日:2008-05-27

    申请号:US10489564

    申请日:2002-08-28

    IPC分类号: A61K39/395

    摘要: The present invention is directed to an immune complex composition, and a method of using that complex to enhance an in viva immune response against a preselected target antigen. The immune complexes of the present invention comprise a monoclonal antibody specific for binding to complement receptor (CR2) site on B lymphocytes linked to a target antigen. As shown in FIG. SA-SD immune complexes bound to monkey B cells are removed in concert with loss of CR2. FIGS. SA and SB demonstrate the % A1488 HB135 and % APhCy CD21 positive cells, out of the doubly positive FE CD20/PerCF CD45 population over time, after injection of A1488 labeled HB135 (an anti-CR2 antibody, administration indicated by first arrow) followed by injection of rabbit anti-mouse IgG (administration indicated by the second arrow). FIGS. SC and SD are plots of the molecules of equivalent soluble fluorochome (MESF) values for these populations.

    摘要翻译: 本发明涉及免疫复合物组合物,以及使用该复合物以增强针对预选靶抗原的血液免疫应答的方法。 本发明的免疫复合物包含对与靶抗原连接的B淋巴细胞上的补体受体(CR2)位点结合有特异性的单克隆抗体。 如图所示。 与猴B细胞结合的SA-SD免疫复合物与CR2的丧失一起被去除。 图 SA和SB在注射A1488标记的HB135(抗CR2抗体,由第一个箭头表示的给药)后,证明了在双倍阳性FE CD20 / PerCF CD45群体中随时间推移的%A1488 HB135和%APhCy CD21阳性细胞, 注射兔抗小鼠IgG(由第二个箭头表示的给药)。 图 SC和SD是这些种群的等效可溶性荧光素(MESF)值分子的图。

    Methods for the prevention and treatment of cancer using anti-C3b(i) antibodies
    3.
    发明授权
    Methods for the prevention and treatment of cancer using anti-C3b(i) antibodies 失效
    使用抗C3b(i)抗体预防和治疗癌症的方法

    公开(公告)号:US06572856B1

    公开(公告)日:2003-06-03

    申请号:US09724620

    申请日:2000-11-28

    IPC分类号: A61K39395

    摘要: The present invention relates to the treatment and prevention of cancer, viral infections and microbial infections by the administration of anti-C3b(i) antibodies. The present invention also relates to methods of treating and preventing cancer, viral infection, or microbial infection in an animal comprising administering to said animal IgG antibodies, IgM antibodies and/or complement components in combination with antibodies specific for C3b(i). The present invention also relates methods of treating and preventing cancer, viral infection or microbial infection in an animal comprising administrating said animal antibodies that immunospecifically bind to one or more cancer cell antigens, viral antigens or microbial antigens, respectively, in combination with antibodies immunospecific for C3b(i). The present invention further relates to the detection, imaging, diagnosis and monitoring of cancer utilizing C3b(i) specific antibodies.

    摘要翻译: 本发明涉及通过施用抗C3b(i)抗体来治疗和预防癌症,病毒感染和微生物感染。 本发明还涉及治疗和预防动物中的癌症,病毒感染或微生物感染的方法,包括向所述动物IgG抗体,IgM抗体和/或补体成分与C3b(i)特异的抗体组合施用。 本发明还涉及治疗和预防动物中的癌症,病毒感染或微生物感染的方法,其包括分别将免疫特异性结合一种或多种癌细胞抗原,病毒抗原或微生物抗原的所述动物抗体与免疫特异性抗体 C3b(i)。 本发明还涉及使用C3b(i)特异性抗体的癌症的检测,成像,诊断和监测。